Apimeds Pharmaceuticals US, Inc. (APUS) — Financial Flexibility Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Financial Flexibility Index of -0.15x as of March 2026. Free cash flow of $-2.13 Million (operating CF $-2.14 Million minus capex $9.39K) represents 0% of total liabilities ($14.70 Million). Check APUS goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Apimeds Pharmaceuticals US, Inc. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Apimeds Pharmaceuticals US, Inc. across 5 annual periods. For the full cash flow conversion analysis, see APUS operating cash flow.
Annual Financial Flexibility Index for Apimeds Pharmaceuticals US, Inc. (2021–2025)
Year-by-year free cash flow to debt coverage for Apimeds Pharmaceuticals US, Inc.. Explore APUS cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.82x | $-8.87 Million | $-8.93 Million | $10.84 Million | ▼ -53.0% |
| 2024 | -0.53x | $-733.53K | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $-823.11K | $410.65K | — |